Winner Medical Valuation
Is 300888 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300888 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300888 (CN¥33.4) is trading below our estimate of fair value (CN¥43.87)
Significantly Below Fair Value: 300888 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300888?
Key metric: As 300888 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 300888's PS Ratio? | |
|---|---|
| PS Ratio | 2.4x |
| Sales | CN¥8.24b |
| Market Cap | CN¥19.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 22.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 300888's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.2x | ||
600529 Shandong Pharmaceutical GlassLtd | 3.3x | 13.6% | CN¥16.7b |
300595 Autek China | 9.3x | 18.2% | CN¥17.1b |
301371 Harbin Fuerjia Technology | 6.7x | 11.0% | CN¥13.8b |
603658 Autobio Diagnostics | 5.7x | 15.9% | CN¥26.3b |
300888 Winner Medical | 2.4x | 16.6% | CN¥19.4b |
Price-To-Sales vs Peers: 300888 is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (6.2x).
Price to Sales Ratio vs Industry
How does 300888's PS Ratio compare vs other companies in the CN Medical Equipment Industry?
Price-To-Sales vs Industry: 300888 is good value based on its Price-To-Sales Ratio (2.4x) compared to the CN Medical Equipment industry average (6.3x).
Price to Sales Ratio vs Fair Ratio
What is 300888's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.4x |
| Fair PS Ratio | 3.5x |
Price-To-Sales vs Fair Ratio: 300888 is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥33.40 | CN¥36.00 +7.8% | 2.3% | CN¥37.00 | CN¥35.00 | n/a | 3 |
| Nov ’25 | CN¥31.87 | CN¥35.50 +11.4% | 1.4% | CN¥36.00 | CN¥35.00 | n/a | 2 |
| Oct ’25 | CN¥31.80 | CN¥34.67 +9.0% | 3.6% | CN¥36.00 | CN¥33.00 | n/a | 3 |
| Sep ’25 | CN¥25.57 | CN¥33.67 +31.7% | 7.8% | CN¥36.00 | CN¥30.00 | n/a | 3 |
| Aug ’25 | CN¥26.03 | CN¥37.77 +45.1% | 7.0% | CN¥41.30 | CN¥35.00 | n/a | 3 |
| Jul ’25 | CN¥25.68 | CN¥37.77 +47.1% | 7.0% | CN¥41.30 | CN¥35.00 | n/a | 3 |
| Jun ’25 | CN¥29.82 | CN¥37.77 +26.6% | 7.0% | CN¥41.30 | CN¥35.00 | n/a | 3 |
| May ’25 | CN¥31.30 | CN¥39.43 +26.0% | 8.0% | CN¥42.00 | CN¥35.00 | n/a | 3 |
| Apr ’25 | CN¥35.35 | CN¥42.33 +19.8% | 14.5% | CN¥50.00 | CN¥35.00 | n/a | 3 |
| Mar ’25 | CN¥35.47 | CN¥42.33 +19.3% | 14.5% | CN¥50.00 | CN¥35.00 | n/a | 3 |
| Feb ’25 | CN¥31.73 | CN¥46.17 +45.5% | 7.1% | CN¥50.00 | CN¥42.00 | n/a | 3 |
| Jan ’25 | CN¥37.25 | CN¥46.17 +23.9% | 7.1% | CN¥50.00 | CN¥42.00 | n/a | 3 |
| Dec ’24 | CN¥38.71 | CN¥48.82 +26.1% | 11.1% | CN¥56.78 | CN¥42.00 | n/a | 4 |
| Nov ’24 | CN¥40.40 | CN¥48.82 +20.8% | 11.1% | CN¥56.78 | CN¥42.00 | CN¥31.87 | 4 |
| Oct ’24 | CN¥41.06 | CN¥55.94 +36.3% | 6.5% | CN¥60.00 | CN¥50.00 | CN¥31.80 | 4 |
| Sep ’24 | CN¥42.56 | CN¥55.94 +31.4% | 6.5% | CN¥60.00 | CN¥50.00 | CN¥25.57 | 4 |
| Aug ’24 | CN¥43.21 | CN¥56.84 +31.5% | 4.0% | CN¥60.00 | CN¥53.57 | CN¥26.03 | 4 |
| Jul ’24 | CN¥41.67 | CN¥55.94 +34.3% | 2.5% | CN¥57.00 | CN¥53.57 | CN¥25.68 | 4 |
| Jun ’24 | CN¥42.49 | CN¥55.98 +31.8% | 2.5% | CN¥57.14 | CN¥53.57 | CN¥29.82 | 4 |
| May ’24 | CN¥43.39 | CN¥55.71 +28.4% | 2.8% | CN¥57.14 | CN¥53.57 | CN¥31.30 | 3 |
| Apr ’24 | CN¥47.29 | CN¥66.43 +40.5% | 0.9% | CN¥67.14 | CN¥65.71 | CN¥35.35 | 3 |
| Mar ’24 | CN¥50.46 | CN¥64.45 +27.7% | 5.4% | CN¥67.14 | CN¥58.51 | CN¥35.47 | 4 |
| Feb ’24 | CN¥52.54 | CN¥64.45 +22.7% | 5.4% | CN¥67.14 | CN¥58.51 | CN¥31.73 | 4 |
| Jan ’24 | CN¥51.07 | CN¥63.55 +24.4% | 5.6% | CN¥66.43 | CN¥58.51 | CN¥37.25 | 3 |
| Dec ’23 | CN¥49.10 | CN¥63.55 +29.4% | 5.6% | CN¥66.43 | CN¥58.51 | CN¥38.71 | 3 |
| Nov ’23 | CN¥48.56 | CN¥63.55 +30.9% | 5.6% | CN¥66.43 | CN¥58.51 | CN¥40.40 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Shenzhen Lifotronic Technology
CN¥7.1b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥16.32
7D
-6.6%
1Y
-29.4%
iRay Technology
CN¥16.0b
Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.
688301
CN¥113.32
7D
-9.3%
1Y
-31.7%
Chison Medical Technologies
CN¥2.9b
Manufactures and sells diagnostic ultrasound systems in China and internationally.
688358
CN¥24.86
7D
-7.0%
1Y
-45.4%